CA2603873A1 - Abuse-resistant amphetamine prodrugs - Google Patents

Abuse-resistant amphetamine prodrugs Download PDF

Info

Publication number
CA2603873A1
CA2603873A1 CA002603873A CA2603873A CA2603873A1 CA 2603873 A1 CA2603873 A1 CA 2603873A1 CA 002603873 A CA002603873 A CA 002603873A CA 2603873 A CA2603873 A CA 2603873A CA 2603873 A1 CA2603873 A1 CA 2603873A1
Authority
CA
Canada
Prior art keywords
amphetamine
lysine
pharmaceutical composition
auc
bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603873A
Other languages
English (en)
French (fr)
Inventor
Travis Mickle
Suma Krishnan
Barney Bishop
James Scott Moncrief
Christopher Lauderback
Rob Oberlender
Thomas Piccariello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603873A1 publication Critical patent/CA2603873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002603873A 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs Abandoned CA2603873A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US66938505P 2005-04-08 2005-04-08
US66938605P 2005-04-08 2005-04-08
US60/669,386 2005-04-08
US60/669,385 2005-04-08
US68117005P 2005-05-16 2005-05-16
US60/681,170 2005-05-16
US75654806P 2006-01-06 2006-01-06
US60/756,548 2006-01-06
US75995806P 2006-01-19 2006-01-19
US60/759,958 2006-01-19
PCT/US2006/013221 WO2006121552A2 (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs

Publications (1)

Publication Number Publication Date
CA2603873A1 true CA2603873A1 (en) 2006-11-16

Family

ID=37397039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603873A Abandoned CA2603873A1 (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs

Country Status (6)

Country Link
EP (1) EP1865980A4 (https=)
JP (1) JP2008535860A (https=)
BR (1) BRPI0612440A2 (https=)
CA (1) CA2603873A1 (https=)
MX (1) MX2007012507A (https=)
WO (1) WO2006121552A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2010042120A1 (en) 2008-10-09 2010-04-15 Archimica, Inc. Process for the synthesis of amphetamine derivatives
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
WO2018118903A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Noncrushable pill formulatiions
US11879019B2 (en) 2016-12-19 2024-01-23 The Regents Of The University Of California Dual-enzyme responsive peptides
DK3459538T3 (da) 2017-09-20 2020-08-03 Sandoz Ag Krystallinske salte af et dextroamfetamin-prodrug
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
PL3845215T3 (pl) * 2019-12-30 2022-11-21 Labomed Pharmaceutical Company S.A. Doustne roztwory zawierające sole lisdeksamfetaminy
WO2022106947A1 (en) 2020-11-18 2022-05-27 Liechti Matthias Emanuel Mdma prodrugs to assist psychotherapy
WO2023111325A1 (en) 2021-12-16 2023-06-22 Labomed Pharmaceutical Company S.A. Container comprising a lisdexamfetamine containing oral solution
WO2024023367A1 (en) 2022-07-29 2024-02-01 Labomed Pharmaceutical Company S.A. Lisdexamfetamine containing oral solution

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US6384020B1 (en) * 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
ATE357228T1 (de) * 2001-05-25 2007-04-15 Cephalon Inc Feste pharmazeutische formulierung enthaltend modafinil
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
EP1675555A4 (en) * 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE

Also Published As

Publication number Publication date
EP1865980A2 (en) 2007-12-19
WO2006121552A9 (en) 2007-03-08
JP2008535860A (ja) 2008-09-04
WO2006121552A3 (en) 2007-07-05
WO2006121552A2 (en) 2006-11-16
EP1865980A4 (en) 2009-11-11
BRPI0612440A2 (pt) 2010-11-23
MX2007012507A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
US7678771B2 (en) Abuse-resistant amphetamine prodrugs
US7678770B2 (en) Abuse-resistant amphetamine prodrugs
CA2603873A1 (en) Abuse-resistant amphetamine prodrugs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130314